Spruce Biosciences (SPRB) Competitors $0.14 +0.01 (+5.27%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. NNVC, OVID, BCAB, LSTA, ANVS, CDIO, ENLV, PMN, MTEX, and ALLRShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include NanoViricides (NNVC), Ovid Therapeutics (OVID), BioAtla (BCAB), Lisata Therapeutics (LSTA), Annovis Bio (ANVS), Cardio Diagnostics (CDIO), Enlivex Therapeutics (ENLV), ProMIS Neurosciences (PMN), Mannatech (MTEX), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. NanoViricides Ovid Therapeutics BioAtla Lisata Therapeutics Annovis Bio Cardio Diagnostics Enlivex Therapeutics ProMIS Neurosciences Mannatech Allarity Therapeutics Spruce Biosciences (NASDAQ:SPRB) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and risk. Is SPRB or NNVC more profitable? NanoViricides has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat NanoViricides' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% NanoViricides N/A -87.90%-78.69% Do analysts rate SPRB or NNVC? Spruce Biosciences currently has a consensus price target of $2.17, suggesting a potential upside of 1,448.73%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than NanoViricides.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00NanoViricides 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, SPRB or NNVC? Spruce Biosciences has a beta of 2.39, suggesting that its share price is 139% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Does the MarketBeat Community prefer SPRB or NNVC? Spruce Biosciences received 39 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 54.17% of users gave Spruce Biosciences an outperform vote while only 0.00% of users gave NanoViricides an outperform vote. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3954.17% Underperform Votes3345.83% NanoViricidesOutperform VotesNo VotesUnderperform Votes57100.00% Does the media prefer SPRB or NNVC? In the previous week, Spruce Biosciences had 5 more articles in the media than NanoViricides. MarketBeat recorded 5 mentions for Spruce Biosciences and 0 mentions for NanoViricides. Spruce Biosciences' average media sentiment score of 0.85 beat NanoViricides' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Overall Sentiment Spruce Biosciences Positive NanoViricides Neutral Do insiders & institutionals believe in SPRB or NNVC? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, SPRB or NNVC? NanoViricides has lower revenue, but higher earnings than Spruce Biosciences. NanoViricides is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M1.20-$47.92M-$1.28-0.11NanoViricidesN/AN/A-$8.29M-$0.72-1.88 SummarySpruce Biosciences beats NanoViricides on 13 of the 16 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.61M$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.157.0522.2318.31Price / Sales1.20273.45398.02107.04Price / CashN/A65.6738.2034.62Price / Book0.076.506.824.25Net Income-$47.92M$142.50M$3.20B$247.51M7 Day Performance17.86%8.32%5.78%6.86%1 Month Performance-56.69%-5.61%-4.31%-2.95%1 Year Performance-80.04%0.11%17.88%5.17% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.8579 of 5 stars$0.14+5.3%$2.17+1,448.7%-80.1%$5.61M$4.91M-0.1520Positive NewsGap UpHigh Trading VolumeNNVCNanoViricidesN/A$1.30-2.3%N/A+17.4%$20.33MN/A-1.8120Gap DownOVIDOvid Therapeutics4.2444 of 5 stars$0.29-1.1%$3.03+962.8%-89.3%$20.29M$566,000.00-0.6160News CoverageGap UpBCABBioAtla2.699 of 5 stars$0.34+4.7%$6.00+1,670.4%-80.6%$19.79M$11M-0.2060News CoverageGap UpLSTALisata Therapeutics2.3074 of 5 stars$2.28+0.9%$15.00+557.9%-12.6%$19.65M$1M-0.9130ANVSAnnovis Bio1.4263 of 5 stars$1.36+11.5%$37.00+2,620.6%-87.2%$19.36MN/A-0.303High Trading VolumeCDIOCardio Diagnostics1.7642 of 5 stars$0.37-5.1%$2.00+440.5%-30.7%$19.29M$34,890.000.001Negative NewsGap UpENLVEnlivex Therapeutics3.0589 of 5 stars$0.88+2.3%$10.00+1,036.4%-36.0%$18.84MN/A-0.9070PMNProMIS Neurosciences2.8599 of 5 stars$0.57-10.7%$6.00+958.2%-71.2%$18.54MN/A-5.675Gap DownMTEXMannatech0.8193 of 5 stars$9.40-1.1%N/A+31.7%$17.87M$117.87M-11.60250Gap UpALLRAllarity Therapeutics0.1165 of 5 stars$1.03+9.6%N/A-97.4%$17.53MN/A0.0010 Related Companies and Tools Related Companies NanoViricides Competitors Ovid Therapeutics Competitors BioAtla Competitors Lisata Therapeutics Competitors Annovis Bio Competitors Cardio Diagnostics Competitors Enlivex Therapeutics Competitors ProMIS Neurosciences Competitors Mannatech Competitors Allarity Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SPRB Stock Free SPRB Stock Alerts